Cargando…

Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis

OBJECTIVES: This study aimed to evaluate the effectiveness of ruxolitinib and compare it with the best available therapy in patients with primary myelofibrosis. Ruxolitinib is a Janus kinase inhibitor that is approved for the treatment of myelofibrosis. The therapeutic protocol has changed after the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasan, Kawa M., Elmeshhadany, Ahmed Y., Shabila, Nazar P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sultan Qaboos University Medical Journal, College of Medicine & Health Sciences 2022
Materias:	Clinical & Basic Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423752/ https://www.ncbi.nlm.nih.gov/pubmed/36072080 http://dx.doi.org/10.18295/squmj.8.2021.110

Ejemplares similares

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
por: Gómez-Casares, María Teresa, et al.
Publicado: (2017)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
por: Kvasnicka, Hans Michael, et al.
Publicado: (2018)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
por: McMullin, Mary Frances, et al.
Publicado: (2015)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
por: Harrison, C N, et al.
Publicado: (2016)

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
por: Harrison, C N, et al.
Publicado: (2017)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
por: Ross, David M., et al.
Publicado: (2021)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
por: Sandhu, Sunny, et al.
Publicado: (2022)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
por: Gupta, Vikas, et al.
Publicado: (2020)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
por: Peng, Yizhou, et al.
Publicado: (2020)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2017)

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
por: Pugliese, Novella, et al.
Publicado: (2019)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis
por: Koschmieder, Steffen, et al.
Publicado: (2020)

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
por: Frankel, Arthur E., et al.
Publicado: (2021)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
por: Maffioli, Margherita, et al.
Publicado: (2022)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib
por: Shanthosh Kumar, Sandhya, et al.
Publicado: (2021)

Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review
por: Ciochetto, Zachary, et al.
Publicado: (2022)

Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study
por: Koyuncu, Mahmut B, et al.
Publicado: (2022)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2o44qm00h3k8cp25knj38s93m1